Evaluation of Pharmacokinetics, Safety, And Tolerability Of Ertugliflozin (PF-04971729, MK-8835) In Japanese And Western Healthy Participants (MK-8835-041)

Inclusion Criteria: * Healthy male and/or female subjects of non-childbearing potential, between the ages of 18 and 55 years, inclusive * Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs). * Japanese subjects must have four Japanese grandparents who were born in Japan. * Mean body weight and the body weight range of Western subjects are similar to those of Japanese subjects with a 10% plus and minus error. * An informed consent document signed and dated by the subject. * Subjects who are willing and able to comply with scheduled visits, treatment plan,laboratory tests, and other study procedures. Exclusion Criteria: * Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease * Asian or Polynesian subjects in Western subject groups. * Any condition possibly affecting drug absorption (eg, gastrectomy). * A positive urine drug screen. * History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males within 6 months of screening. * History or evidence of habitual use of tobacco or nicotine containing products within 3 months of Screening, with the exception of light smoking (up to 5 cigarettes per day or the equivalent). * Treatment with an investigational drug within 30 days or 5 half-lives preceding the first dose of study medication. * 12-lead ECG demonstrating QTc \>450 msec at screening. * Subjects with ANY of the following abnormalities on safety laboratory tests): * Evidence of glycosuria, as defined by a positive urine dipstick test; * Fasting serum triglyceride \>300 mg/dL; * Fasting LDL-cholesterol \> than or equal to 190 mg/dL. * Fasting serum glucose \>125 mg/dL.